GH Research Shares Rise Ahead of Release of Clinical-Trial Results

Dow Jones

02/01

By Connor Hart

Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression.

The stock rose 5.2%, to $11.15, in after-hours trading on Friday. Shares ended the regular session 9.4% higher, at $10.60, putting them up 39% in the past year.

The biopharmaceutical company said it would host a webcast Monday morning to discuss data from its Phase 2b trial of its lead product candidate, GH001.

In December 2021, the Dublin company said the drug met the primary endpoint of the Phase 2 part of its Phase 1/2 trial, as seven out of eight patients achieved remission after a week of using the treatment.

The company said it believes that GH001 has the potential to change the way treatment-resistant depression is managed.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

January 31, 2025 17:43 ET (22:43 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2508913784"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2508913784\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2508913784?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-01 06:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2508913784","market":"sg","top_or_hot":-1,"title":"GH Research Shares Rise Ahead of Release of Clinical-Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. \n</p>\n<p>\n  The stock rose 5.2%, to $11.15, in after-hours trading on Friday. Shares ended the regular session 9.4% higher, at $10.60, putting them up 39% in the past year. \n</p>\n<p>\n  The biopharmaceutical company said it would host a webcast Monday morning to discuss data from its Phase 2b trial of its lead product candidate, GH001. \n</p>\n<p>\n  In December 2021, the Dublin company said the drug met the primary endpoint of the Phase 2 part of its Phase 1/2 trial, as seven out of eight patients achieved remission after a week of using the treatment. \n</p>\n<p>\n  The company said it believes that GH001 has the potential to change the way treatment-resistant depression is managed. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 31, 2025 17:43 ET (22:43 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research Shares Rise Ahead of Release of Clinical-Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research Shares Rise Ahead of Release of Clinical-Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-01 06:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. \n</p>\n<p>\n  The stock rose 5.2%, to $11.15, in after-hours trading on Friday. Shares ended the regular session 9.4% higher, at $10.60, putting them up 39% in the past year. \n</p>\n<p>\n  The biopharmaceutical company said it would host a webcast Monday morning to discuss data from its Phase 2b trial of its lead product candidate, GH001. \n</p>\n<p>\n  In December 2021, the Dublin company said the drug met the primary endpoint of the Phase 2 part of its Phase 1/2 trial, as seven out of eight patients achieved remission after a week of using the treatment. \n</p>\n<p>\n  The company said it believes that GH001 has the potential to change the way treatment-resistant depression is managed. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 31, 2025 17:43 ET (22:43 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2508913784","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2508913784","pubTimestamp":1738363380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression.The stock rose 5.2%, to $11.15, in after-hours trading on Friday. Shares ended the regular session 9.4% higher, at $10.60, putting them up 39% in the past year.The biopharmaceutical company said it would host a webcast Monday morning to discuss data from its Phase 2b trial of its lead product candidate, GH001.In December 2021, the Dublin company said the drug met the primary endpoint of the Phase 2 part of its Phase 1/2 trial, as seven out of eight patients achieved remission after a week of using the treatment.The company said it believes that GH001 has the potential to change the way treatment-resistant depression is managed.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓","GH":"Guardant Health Inc.","BK4539":"次新股","GHRS":"GH Research PLC","BK4007":"制药","BK4551":"寇图资本持仓","BK4588":"碎股","BK4196":"保健护理服务"},"translate_title":"GH Research股价在临床试验结果发布前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GHRS":0.9,"GH":1},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. \n\n\n  The stock rose 5.2%, to $11.15, in after-hours trading on Friday. Shares ended the regular session 9.4% higher, at $10.60, putting them up 39% in the past year. \n\n\n  The biopharmaceutical company said it would host a webcast Monday morning to discuss data from its Phase 2b trial of its lead product candidate, GH001. \n\n\n  In December 2021, the Dublin company said the drug met the primary endpoint of the Phase 2 part of its Phase 1/2 trial, as seven out of eight patients achieved remission after a week of using the treatment. \n\n\n  The company said it believes that GH001 has the potential to change the way treatment-resistant depression is managed. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 31, 2025 17:43 ET (22:43 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}